NCT04205175 - A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

October 31, 2022

Study Completion Date

October 31, 2022

Conditions

Hemophilia A With Inhibitor

Interventions

DRUG

Feiba

This is a single center, open label, dose escalation study of in vivo administration of Feiba in congenital hemophilia A patients with inhibitors who are on emicizumab.

Trial Locations (1)

90027

Childrens Hospital Los Angeles, Los Angeles